Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study

H Sorbye; S Welin; S W Langer; L W Vestermark; N Holt; P Osterlund; S Dueland; E Hofsli; M G Guren; K Ohrling; E Birkemeyer; E Thiis-Evensen; Matteo Biagini; H Gronbaek; L M Soveri; I H Olsen; B Federspiel; J Assmus; E T Janson; U Knigge

doi:10.1093/annonc/mds276

Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study

H Sorbye, S Welin, S W Langer, L W Vestermark, N Holt, P Osterlund, S Dueland, E Hofsli, M G Guren, K Ohrling, E Birkemeyer, E Thiis-Evensen, Matteo Biagini, H Gronbaek, L M Soveri, I H Olsen, B Federspiel, J Assmus, E T Janson, U Knigge

501 Citations (Scopus)

Abstract

Background As studies on gastrointestinal neuroendocrine carcinoma (WHO G3) (GI-NEC) are limited, we reviewed clinical data to identify predictive and prognostic markers for advanced GI-NEC patients. Patients and methods Data from advanced GI-NEC patients diagnosed 2000-2009 were retrospectively registered at 12 Nordic hospitals. Results The median survival was 11 months in 252 patients given palliative chemotherapy and 1 month in 53 patients receiving best supportive care (BSC) only. The response rate to first-line chemotherapy was 31% and 33% had stable disease. Ki-67

Original language	English
Journal	Annals of Oncology
Volume	24
Issue number	1
Pages (from-to)	152-60
Number of pages	9
ISSN	0923-7534
DOIs	https://doi.org/10.1093/annonc/mds276
Publication status	Published - Jan 2013

Access to Document

10.1093/annonc/mds276

Cite this

Sorbye, H., Welin, S., Langer, S. W., Vestermark, L. W., Holt, N., Osterlund, P., Dueland, S., Hofsli, E., Guren, M. G., Ohrling, K., Birkemeyer, E., Thiis-Evensen, E., Biagini, M., Gronbaek, H., Soveri, L. M., Olsen, I. H., Federspiel, B., Assmus, J., Janson, E. T., & Knigge, U. (2013). Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. Annals of Oncology, 24(1), 152-60. https://doi.org/10.1093/annonc/mds276

Sorbye, H, Welin, S, Langer, SW, Vestermark, LW, Holt, N, Osterlund, P, Dueland, S, Hofsli, E, Guren, MG, Ohrling, K, Birkemeyer, E, Thiis-Evensen, E, Biagini, M, Gronbaek, H, Soveri, LM, Olsen, IH, Federspiel, B, Assmus, J, Janson, ET & Knigge, U 2013, 'Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study', Annals of Oncology, vol. 24, no. 1, pp. 152-60. https://doi.org/10.1093/annonc/mds276

@article{cd1851c7f1aa4d45aa4baf84a19f1119,

title = "Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study",

abstract = "Background As studies on gastrointestinal neuroendocrine carcinoma (WHO G3) (GI-NEC) are limited, we reviewed clinical data to identify predictive and prognostic markers for advanced GI-NEC patients. Patients and methods Data from advanced GI-NEC patients diagnosed 2000-2009 were retrospectively registered at 12 Nordic hospitals. Results The median survival was 11 months in 252 patients given palliative chemotherapy and 1 month in 53 patients receiving best supportive care (BSC) only. The response rate to first-line chemotherapy was 31% and 33% had stable disease. Ki-67 ",

author = "H Sorbye and S Welin and Langer, {S W} and Vestermark, {L W} and N Holt and P Osterlund and S Dueland and E Hofsli and Guren, {M G} and K Ohrling and E Birkemeyer and E Thiis-Evensen and Matteo Biagini and H Gronbaek and Soveri, {L M} and Olsen, {I H} and B Federspiel and J Assmus and Janson, {E T} and U Knigge",

year = "2013",

month = jan,

doi = "10.1093/annonc/mds276",

language = "English",

volume = "24",

pages = "152--60",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3)

T2 - The NORDIC NEC study

AU - Sorbye, H

AU - Welin, S

AU - Langer, S W

AU - Vestermark, L W

AU - Holt, N

AU - Osterlund, P

AU - Dueland, S

AU - Hofsli, E

AU - Guren, M G

AU - Ohrling, K

AU - Birkemeyer, E

AU - Thiis-Evensen, E

AU - Biagini, Matteo

AU - Gronbaek, H

AU - Soveri, L M

AU - Olsen, I H

AU - Federspiel, B

AU - Assmus, J

AU - Janson, E T

AU - Knigge, U

PY - 2013/1

Y1 - 2013/1

N2 - Background As studies on gastrointestinal neuroendocrine carcinoma (WHO G3) (GI-NEC) are limited, we reviewed clinical data to identify predictive and prognostic markers for advanced GI-NEC patients. Patients and methods Data from advanced GI-NEC patients diagnosed 2000-2009 were retrospectively registered at 12 Nordic hospitals. Results The median survival was 11 months in 252 patients given palliative chemotherapy and 1 month in 53 patients receiving best supportive care (BSC) only. The response rate to first-line chemotherapy was 31% and 33% had stable disease. Ki-67

AB - Background As studies on gastrointestinal neuroendocrine carcinoma (WHO G3) (GI-NEC) are limited, we reviewed clinical data to identify predictive and prognostic markers for advanced GI-NEC patients. Patients and methods Data from advanced GI-NEC patients diagnosed 2000-2009 were retrospectively registered at 12 Nordic hospitals. Results The median survival was 11 months in 252 patients given palliative chemotherapy and 1 month in 53 patients receiving best supportive care (BSC) only. The response rate to first-line chemotherapy was 31% and 33% had stable disease. Ki-67

U2 - 10.1093/annonc/mds276

DO - 10.1093/annonc/mds276

M3 - Journal article

C2 - 22967994

SN - 0923-7534

VL - 24

SP - 152

EP - 160

JO - Annals of Oncology

JF - Annals of Oncology

IS - 1

ER -

Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study

Abstract

Access to Document

Fingerprint

Cite this